Latest stories on PHVS
Pharvaris N.V. (PHVS) Presents at 2026 HAEi Regional Conference Americas - Slideshow
Seeking Alpha52 · neutralproduct/pr
Bank of America backs Pharvaris on breakthrough for rare swelling disease
The Street63 · neutralanalyst
Pharvaris rises after BofA upgrades to Buy
Seeking Alpha64 · neutralanalyst
BofA upgrades Pharvaris stock rating on oral HAE treatment potential
Investing.com Analyst Ratings64 · neutralanalyst
Pharvaris upgraded to Buy at BofA after ‘valuation reset’
The Fly64 · neutralanalyst
Pharvaris upgraded to Buy from Neutral at BofA
The Fly64 · neutralanalyst
Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial
The Fly74 · bullishproduct/pr
Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Cantor Fitzgerald reiterates Pharvaris stock rating after trial data
Investing.com Analyst Ratings56 · neutralanalyst
Guggenheim raises Pharvaris stock price target on trial results
Investing.com Analyst Ratings61 · neutralanalyst
Pharvaris price target raised to $44 from $40 at Guggenheim
The Fly61 · neutralanalyst
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win
Seeking Alpha73 · bullishproduct/pr
Pharvaris price target raised to $50 from $42 at Wedbush
The Fly61 · neutralanalyst
Pharvaris price target raised to $65 from $50 at Leerink
The Fly67 · bullishanalyst
Pharvaris price target raised to $62 from $52 at RBC Capital
The Fly65 · bullishanalyst
Pharvaris price target raised to $62 from $46 at Morgan Stanley
The Fly67 · bullishanalyst
Pharvaris price target raised to $65 from $55 at Wells Fargo
The Fly67 · bullishanalyst
Wells Fargo raises Pharvaris stock price target on strong trial data
Investing.com Analyst Ratings63 · neutralanalyst
Pharvaris price target raised to $65 from $52 at Jones
The Fly63 · neutralanalyst
Pharvaris price target raised to $79 from $75 at Citizens
The Fly63 · neutralanalyst
Citizens raises Pharvaris stock price target to $79 on HAE therapy
Investing.com Analyst Ratings61 · neutralanalyst
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
Stocktwits News28 · bearishproduct/pr
Oppenheimer raises Pharvaris stock price target on trial results
Investing.com Analyst Ratings63 · neutralanalyst
Pharvaris price target raised to $75 from $50 at Oppenheimer
The Fly67 · bullishanalyst